好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Comparison of Levetiracetam vs Carbamazepine in Epilepsy Patients: A Systematic Review
Epilepsy/Clinical Neurophysiology (EEG)
P1 - Poster Session 1 (9:00 AM-5:00 PM)
150

This systematic review aims to compare the efficacy of levetiracetam (LEV) and carbamazepine (CBZ).

LEV is a relatively novel anti-epileptic drug with better tolerance and safety than older anti-epileptic drug such as CBZ. However, clinical comparison of the efficacy of these two drugs is still unclear.

We searched data from PubMed, PMC, Science Direct, Google Scholar, and by hand searching, on 30 September 2021, using combination of keywords associated levetiracetam, carbamazepine and its efficacy, measured by seizure free rate at 6 and 12 months and adverse drug event such as agitation, diarrhea, and skin rashes in epileptic patients. We included randomized clinical trials (RCTs) performed in patient newly diagnosed with partial or generalized seizures with clear focal origin or generalized tonic–clonic seizures without clear focal origin, experienced more than 2 unprovoked seizures separated by at least 48 hours during the past year with at least 1 seizure during the previous 3 months with no age restriction, publications are limited to English manuscripts that were published in the last 20 years. We excluded studies that only explored one of the two drugs, cohorts, case report and case series. All studies are reviewed and evaluated by all 5 authors. The quality of each included studies was assessed using JADAD Scale.

A total of 10 RCT consisting of 4451 patients were included. Based on JADAD scale, 6 RCT were good quality while 4 were fair quality. 7 studies showed that LEV seizure free rate and adverse drug event are comparable with CBZ with no significant superiority between the two, while 3 studies showed that LEV have better seizure free rate and fewer side effect.

Current studies demonstrated that LEV have comparable effect with CBZ in terms of 6- and 12-month seizure free rate and adverse drug event.

Authors/Disclosures

PRESENTER
No disclosure on file
No disclosure on file
Rivaldo S. Heriyanto Mr. Heriyanto has nothing to disclose.
Rivaldo S. Heriyanto Mr. Heriyanto has nothing to disclose.
No disclosure on file